Skip to main content

Mir-152 inhibits cell proliferation and colony formation of CD133+ liver cancer stem cells by targeting KIT

Tumor Biology volume 36, pages 921–928 (2015)Cite this article

Abstract

miR152 is involved in diverse biological functions and development of disease. This study investigates the role of mir-152 in cell proliferation and colony formation of liver cancer stem cells. We show that exogenous overexpression of mir-152 suppresses cell proliferation and colony formation in CD133+ hep3B cells. We also show that KIT is a direct target of miR-152 and miR-152 downregulates protein expression of KIT by directly binding to 3′ untranslated region of KIT. Downregulation of KIT by specific siRNAs inhibits proliferation and colony formation of CD133+ hep3B cells, which is similar to inhibitory effects of miR-152. Moreover, exogenous expression of KIT compromises inhibitory effects of miR-152 on cell proliferation and colony formation. Our findings suggest that mir-152 inhibits cell proliferation and colony formation of CD133+ hep3B cells by targeting KIT.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014;109(4):542–53. doi:10.1038/ajg.2014.11.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Fan JH, Wang JB, Jiang Y, Xiang W, Liang H, Wei WQ, et al. Attributable causes of liver cancer mortality and incidence in China. Asian Pac J Cancer Prev. 2013;14(12):7251–6.

    Article  PubMed  Google Scholar 

  3. Chen WQ, Zheng RS, Zhang SW. Liver cancer incidence and mortality in China, 2009. Chin J Cancer. 2013;32(4):162–9. doi:10.5732/cjc.013.10027.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Matsuda T, Saika K. Trends in liver cancer mortality rates in Japan, USA, UK, France and Korea based on the WHO mortality database. Jpn J Clin Oncol. 2012;42(4):360–1. doi:10.1093/jjco/hys048.

    Article  PubMed  Google Scholar 

  5. Coviello E, Caputi G, Martinelli D, Germinario CA, Prato R. Mortality trends for primary liver cancer in Puglia. Italy Eur J Cancer Prev. 2010;19(6):417–23. doi:10.1097/CEJ.0b013e32833ad36e.

    Article  PubMed  Google Scholar 

  6. Chiba T, Kamiya A, Yokosuka O, Iwama A. Cancer stem cells in hepatocellular carcinoma: recent progress and perspective. Cancer Lett. 2009;286(2):145–53. doi:10.1016/j.canlet.2009.04.027.

    Article  CAS  PubMed  Google Scholar 

  7. Sukowati CH, Rosso N, Croce LS, Tiribelli C. Hepatic cancer stem cells and drug resistance: relevance in targeted therapies for hepatocellular carcinoma. World J Hepatol. 2010;2(3):114–26. doi:10.4254/wjh.v2.i3.114.

    PubMed  PubMed Central  Google Scholar 

  8. Sukowati CH, Tiribelli C. The biological implication of cancer stem cells in hepatocellular carcinoma: a possible target for future therapy. Expert Rev Gastroenterol Hepatol. 2013;7(8):749–57. doi:10.1586/17474124.2013.846826.

    Article  CAS  PubMed  Google Scholar 

  9. Lee TK, Cheung VC, Ng IO. Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma. Cancer Lett. 2013;338(1):101–9. doi:10.1016/j.canlet.2012.05.001.

    Article  CAS  PubMed  Google Scholar 

  10. Saito T, Chiba T, Yuki K, Zen Y, Oshima M, Koide S, et al. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PLoS One. 2013;8(7):e70010. doi:10.1371/journal.pone.0070010.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. He XX, Chang Y, Meng FY, Wang MY, Xie QH, Tang F, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012;31(28):3357–69. doi:10.1038/onc.2011.500.

    Article  CAS  PubMed  Google Scholar 

  12. Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology. 2013;58(2):629–41. doi:10.1002/hep.26369.

    Article  CAS  PubMed  Google Scholar 

  13. Gao XN, Lin J, Li YH, Gao L, Wang XR, Wang W, et al. MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. Oncogene. 2011;30(31):3416–28. doi:10.1038/onc.2011.62.

    Article  CAS  PubMed  Google Scholar 

  14. Geng L, Chaudhuri A, Talmon G, Wisecarver JL, Are C, Brattain M, et al. MicroRNA-192 suppresses liver metastasis of colon cancer. Oncogene. 2013. doi:10.1038/onc.2013.478.

    PubMed  PubMed Central  Google Scholar 

  15. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, et al. miR-130b promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell. 2010;7(6):694–707. doi:10.1016/j.stem.2010.11.010.

    Article  CAS  PubMed  Google Scholar 

  16. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009;4(8):e6816. doi:10.1371/journal.pone.0006816.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Yu F, Deng H, Yao H, Liu Q, Su F, Song E. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene. 2010;29(29):4194–204. doi:10.1038/onc.2010.167.

    Article  CAS  PubMed  Google Scholar 

  18. Huang J, Wang Y, Guo Y, Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology. 2010;52(1):60–70. doi:10.1002/hep.23660.

    Article  CAS  PubMed  Google Scholar 

  19. Tsuruta T, Kozaki K, Uesugi A, Furuta M, Hirasawa A, Imoto I, et al. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res. 2011;71(20):6450–62. doi:10.1158/0008-5472.CAN-11-0364.

    Article  CAS  PubMed  Google Scholar 

  20. Wang YS, Chou WW, Chen KC, Cheng HY, Lin RT, Juo SH. MicroRNA-152 mediates DNMT1-regulated DNA methylation in the estrogen receptor alpha gene. PLoS One. 2012;7(1):e30635. doi:10.1371/journal.pone.0030635.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Zheng X, Chopp M, Lu Y, Buller B, Jiang F. MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3. Cancer Lett. 2013;329(2):146–54. doi:10.1016/j.canlet.2012.10.026.

    Article  CAS  PubMed  Google Scholar 

  22. Zhu C, Li J, Ding Q, Cheng G, Zhou H, Tao L, et al. miR-152 controls migration and invasive potential by targeting TGFalpha in prostate cancer cell lines. Prostate. 2013;73(10):1082–9. doi:10.1002/pros.22656.

    Article  CAS  PubMed  Google Scholar 

  23. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007;120(7):1444–50. doi:10.1002/ijc.22476.

    Article  CAS  PubMed  Google Scholar 

  24. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132(7):2542–56. doi:10.1053/j.gastro.2007.04.025.

    Article  CAS  PubMed  Google Scholar 

  25. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun. 2006;351(4):820–4. doi:10.1016/j.bbrc.2006.10.128.

    Article  CAS  PubMed  Google Scholar 

  26. Piao LS, Hur W, Kim TK, Hong SW, Kim SW, Choi JE, et al. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett. 2012;315(2):129–37. doi:10.1016/j.canlet.2011.10.012.

    Article  CAS  PubMed  Google Scholar 

  27. Ji D, Chen Z, Li M, Zhan T, Yao Y, Zhang Z, et al. MicroRNA-181a promotes tumor growth and liver metastasis in colorectal cancer by targeting the tumor suppressor WIF-1. Mol Cancer. 2014;13(1):86. doi:10.1186/1476-4598-13-86.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Liang L, Wong CM, Ying Q, Fan DN, Huang S, Ding J, et al. MicroRNA-125b suppressed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology. 2010;52(5):1731–40. doi:10.1002/hep.23904.

    Article  CAS  PubMed  Google Scholar 

  29. Liu X, Zhan Z, Xu L, Ma F, Li D, Guo Z, et al. MicroRNA-148/152 impair innate response and antigen presentation of TLR-triggered dendritic cells by targeting CaMKIIalpha. J Immunol. 2010;185(12):7244–51. doi:10.4049/jimmunol.1001573.

    Article  CAS  PubMed  Google Scholar 

  30. Muto S, Katsuki M, Horie S. Decreased c-kit function inhibits enhanced skin carcinogenesis in c-Ha-ras protooncogene transgenic mice. Cancer Sci. 2007;98(10):1549–56. doi:10.1111/j.1349-7006.2007.00577.x.

    Article  CAS  PubMed  Google Scholar 

  31. Yasuda A, Sawai H, Takahashi H, Ochi N, Matsuo Y, Funahashi H, et al. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells. Mol Cancer. 2006;5:46. doi:10.1186/1476-4598-5-46.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Gavert N, Shvab A, Sheffer M, Ben-Shmuel A, Haase G, Bakos E, et al. c-Kit is suppressed in human colon cancer tissue and contributes to L1-mediated metastasis. Cancer Res. 2013;73(18):5754–63. doi:10.1158/0008-5472.CAN-13-0576.

    Article  CAS  PubMed  Google Scholar 

  33. Wiesner C, Nabha SM, Dos Santos EB, Yamamoto H, Meng H, Melchior SW, et al. C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. Neoplasia. 2008;10(9):996–1003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Chau WK, Ip CK, Mak AS, Lai HC, Wong AS. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling. Oncogene. 2013;32(22):2767–81. doi:10.1038/onc.2012.290.

    Article  CAS  PubMed  Google Scholar 

  35. Siemens H, Jackstadt R, Kaller M, Hermeking H. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget. 2013;4(9):1399–415.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Fan R, Zhong J, Zheng S, Wang Z, Xu Y, Li S, et al. MicroRNA-218 inhibits gastrointestinal stromal tumor cell and invasion by targeting KIT. Tumour Biol. 2013. doi:10.1007/s13277-013-1551-z.

    Google Scholar 

  37. Gao XN, Lin J, Gao L, Li YH, Wang LL, Yu L. MicroRNA-193b regulates c-Kit proto-oncogene and represses cell proliferation in acute myeloid leukemia. Leuk Res. 2011;35(9):1226–32. doi:10.1016/j.leukres.2011.06.010.

    Article  CAS  PubMed  Google Scholar 

  38. Gits CM, van Kuijk PF, Jonkers MB, Boersma AW, van Ijcken WF, Wozniak A, et al. MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours. Br J Cancer. 2013;109(6):1625–35. doi:10.1038/bjc.2013.483.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kim WK, Park M, Kim YK, Tae YK, Yang HK, Lee JM, et al. MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation. Clin Cancer Res. 2011;17(24):7584–94. doi:10.1158/1078-0432.CCR-11-0166.

    Article  CAS  PubMed  Google Scholar 

  40. Koelz M, Lense J, Wrba F, Scheffler M, Dienes HP, Odenthal M. Down-regulation of miR-221 and miR-222 correlates with pronounced Kit expression in gastrointestinal stromal tumors. Int J Oncol. 2011;38(2):503–11. doi:10.3892/ijo.2010.857.

    Article  CAS  PubMed  Google Scholar 

  41. Li P, Ma L, Zhang Y, Ji F, Jin F. MicroRNA-137 down-regulates KIT and inhibits small cell lung cancer cell proliferation. Biomed Pharmacother. 2014;68(1):7–12. doi:10.1016/j.biopha.2013.12.002.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The present study was supported by grants from the Science and Technology Program of Guangdong Province (2008B030301028) and the Science and Technology Innovation Fund of Guangdong Medical College (STI F201107).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Clinical Research Center, the Affiliated Hospital of Guangdong Medical College, 524001, Zhanjiang, China

    Haili Huang & Peng Li

  2. Department of Hepatobiliary Surgery, the Affiliated Hospital of Guangdong Medical College, 524001, Zhanjiang, China

    Min Hu, Caijie Lu & Mingyi Li

Authors
  1. Haili Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Min Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Caijie Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mingyi Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mingyi Li.

Additional information

Haili Huang, Min Hu, and Peng Li contribute equally to this work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOCX 18 kb)

Table S1

(DOC 28 kb)

Figure S1

(DOCX 62 kb)

Figure S2

(DOCX 277 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Huang, H., Hu, M., Li, P. et al. Mir-152 inhibits cell proliferation and colony formation of CD133+ liver cancer stem cells by targeting KIT. Tumor Biol. 36, 921–928 (2015). https://doi.org/10.1007/s13277-014-2719-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2719-x

Keywords

  • miR-152
  • KIT
  • Liver cancer stem cells
  • Proliferation